Prometheus Biosciences, Inc.
Index- P/E- EPS (ttm)-2.32 Insider Own34.82% Shs Outstand39.00M Perf Week28.06%
Market Cap1.02B Forward P/E- EPS next Y-3.71 Insider Trans0.00% Shs Float29.96M Perf Month-13.58%
Income-90.20M PEG- EPS next Q-0.87 Inst Own68.00% Short Float10.59% Perf Quarter-26.51%
Sales3.10M P/S327.88 EPS this Y-244.40% Inst Trans3.96% Short Ratio8.16 Perf Half Y-16.44%
Book/sh6.03 P/B5.03 EPS next Y-1.40% ROA-23.10% Target Price52.25 Perf Year48.19%
Cash/sh7.68 P/C3.95 EPS next 5Y- ROE-25.50% 52W Range16.65 - 51.96 Perf YTD-23.24%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-41.59% Beta-
Dividend %- Quick Ratio16.10 Sales past 5Y- Gross Margin- 52W Low82.28% ATR2.83
Employees72 Current Ratio16.10 Sales Q/Q400.00% Oper. Margin- RSI (14)51.64 Volatility12.59% 10.43%
OptionableYes Debt/Eq0.00 EPS Q/Q-299.60% Profit Margin- Rel Volume1.10 Prev Close27.52
ShortableYes LT Debt/Eq0.00 EarningsMay 12 AMC Payout- Avg Volume389.01K Price30.35
Recom1.40 SMA2011.04% SMA50-14.36% SMA200-5.35% Volume416,001 Change10.28%
Feb-11-22Initiated BTIG Research Buy $62
Dec-13-21Initiated RBC Capital Mkts Outperform $46
Dec-08-21Upgrade Oppenheimer Perform → Outperform $35 → $50
Dec-08-21Initiated Wells Fargo Overweight $42
Nov-15-21Downgrade Oppenheimer Outperform → Perform $35
Nov-12-21Resumed Stifel Buy $45
Oct-05-21Initiated Oppenheimer Outperform $35
Apr-26-21Resumed Credit Suisse Outperform $30
Apr-06-21Initiated SVB Leerink Outperform $34
Apr-06-21Initiated Stifel Buy $25
Apr-06-21Initiated Guggenheim Buy $40
Apr-06-21Initiated Credit Suisse Outperform $30
May-12-22 05:15PM  
May-05-22 07:23AM  
Mar-30-22 08:00AM  
Mar-09-22 04:01PM  
Mar-01-22 08:30AM  
Feb-07-22 05:38PM  
Jan-19-22 04:30AM  
Jan-12-22 08:30AM  
Jan-05-22 08:30AM  
Jan-03-22 08:00AM  
Dec-13-21 12:50PM  
Dec-07-21 07:00AM  
Nov-12-21 08:00AM  
Nov-02-21 08:00AM  
Oct-12-21 04:01PM  
Oct-06-21 06:13AM  
Aug-13-21 05:06AM  
Aug-11-21 04:01PM  
Aug-05-21 07:30AM  
Aug-02-21 08:00AM  
Jul-19-21 12:50PM  
Jul-15-21 08:00AM  
Jun-21-21 09:00AM  
Jun-14-21 06:59AM  
May-25-21 04:05PM  
May-17-21 08:00AM  
May-14-21 04:01PM  
May-13-21 04:01PM  
Apr-07-21 10:34AM  
Mar-16-21 04:05PM  
Mar-11-21 10:26PM  
Prometheus Biosciences, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of precision therapeutics and companion diagnostics products for the treatment and diagnosis of inflammatory bowel diseases (IBD). Its products include PRA023, a Phase I clinical trial IgG1 humanized monoclonal antibody (mAb); PR600, an anti- tumor necrosis factor mAb for IBD; PR300, a G-protein coupled receptor modulator small molecule for IBD; PR1800, anti-chemokine mAb for IBD; and PR2100, an anti-inflammatory cytokine mAb for IBD. The company has a diagnostics development and collaboration agreement with Takeda Pharmaceutical Company Limited; co-development and manufacturing agreement with Dr. Falk Pharma GmbH; license agreement with Cedars-Sinai Medical Center; and strategic collaboration with Millennium Pharmaceuticals, Inc. Prometheus Biosciences, Inc. was formerly known as Precision IBD, Inc. and changed its name to Prometheus Biosciences, Inc. in October 2019. The company was founded in 2016 and is based in San Diego, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
McKenna Mark C.Chairman, President & CEODec 01Option Exercise2.9015,40044,66015,400Dec 03 07:02 PM